At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 121 enrolled
Drug / intervention
ABT-493/ABT-530drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4)
In Brief
A Phase 3 clinical trial evaluating ABT-493/ABT-530 for Hepatitis C Virus. Completed, enrolled 121 participants.
Detailed Summary
The purpose of this study is to evaluate the effect of response to treatment by evaluating the percentage of subjects achieving a 12-week sustained virologic response (SVR12) after 12 weeks of treatment with ABT-493/ABT-530 and to evaluate the safety of the regimen in participants with chronic hepatitis C virus (HCV) genotype (GT) 4, 5, or 6 infection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C Virus
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartNov 2015
First PostedDec 2015
Primary CompletionOct 2016
Study CompletionJan 2017
TodayJul 2026
First PostedDec 22, 2015
Enrollment StartNov 1, 2015
Primary CompletionOct 1, 2016
Study CompletionJan 1, 2017
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 10.5 years ago
Interventions
ABT-493/ABT-530drug
Tablet; ABT-493 coformulated with ABT-530